Targeted therapy for metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeted therapy for metastatic renal cell carcinoma

Published:2020-10-14 Issue:10 Volume:2020 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Hofmann Fabian¹,Hwang Eu Chang²,Lam Thomas BL³,Bex Axel⁴,Yuan Yuhong⁵,Marconi Lorenzo SO⁶,Ljungberg Börje⁷

Affiliation:

1. Department of Urology; Sunderby Sjukhus, Umeå University; Luleå Sweden

2. Department of Urology; Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Hwasun Korea, South

3. Academic Urology Unit; University of Aberdeen; Aberdeen UK

4. Department of Urology and UCL Division of Surgery and Interventional Science; Royal Free London NHS Foundation Trust; London UK

5. Department of Medicine, Division of Gastroenterology; McMaster University; Hamilton Canada

6. Department of Urology and Renal Transplantation; Centro Hospitalar e Universitario de Coimbra; Coimbra Portugal

7. Department of Surgical and Perioperative Sciences; Umeå University; Umeå Sweden

Publisher

Wiley

Subject

Pharmacology (medical)

Reference217 articles.

1. Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer;Eichelberg;Annals of Oncology,2014

2. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer;Eichelberg;European Urology,2015

3. Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC);Goebell;Journal of Clinical Oncology,2014

4. SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC);Michel;Journal of Clinical Oncology,2014

5. Sequential study to treat renal cell carcinoma clinicaltrials.gov/ct2/show/NCT00732914

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma;Expert Review of Pharmacoeconomics & Outcomes Research;2024-09

2. DCS, a novel classifier system based on disulfidptosis reveals tumor microenvironment heterogeneity and guides frontline therapy for clear cell renal carcinoma;Journal of the National Cancer Center;2024-09

3. Immune Checkpoint Inhibitors in Cancer Treatment and Incidence of Pancreatitis;Cureus;2024-08-28

4. Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma;Heliyon;2024-04

5. The Impact of a Multidisciplinary Tumor Board (MTB) on Treatment Decision Making for Patients With Renal Cell Carcinoma (RCC): 5-Year Data Analysis;Clinical Genitourinary Cancer;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3